Exact Sciences Posts Flat Q4 Revenues, Awaits Meeting with FDA about Cologuard | GenomeWeb

NEW YORK (GenomeWeb News) – Exact Sciences today reported flat revenues year over year for its fourth quarter, matching the consensus analyst estimate on the top line and beating it on the bottom line.

The Madison, Wis.-based molecular diagnostics company took in $1.0 million in revenues for the three months ended Dec. 31, 2013, the same as a year ago. Revenues for Q4 2013 and the year-ago period derived from licensing fees.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.